Sanjay Saxena

Dr. Sanjay Saxena

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Sanjay SaxenaSanjay Saxena
Sanjay Saxena
BJBiswajit Jena
Biswajit Jena
NGNeha Gupta
Neha Gupta
SDSuchismita Das
Suchismita Das
DSDeepaneeta Sarmah
Deepaneeta Sarmah
Jasjit SuriJasjit Suri
Jasjit Suri
Radiogenomics, a combination of “Radiomics” and “Genomics,” using Artificial Intelligence (AI) has recently emerged as the state-of-the-art science in precision medicine, especially in oncology care. Radiogenomics syndicates large-scale quantifiable data extracted from radiological medical images enveloped with personalized genomic phenotypes. It fabricates a prediction model through various AI methods to stratify the risk of patients, monitor therapeutic approaches, and assess clinical outcomes. It has recently shown tremendous achievements in prognosis, treatment planning, survival prediction, heterogeneity analysis, reoccurrence, and progression-free survival for human cancer study. Although AI has shown immense performance in oncology care in various clinical aspects, it has several challenges and limitations. The proposed review provides an overview of radiogenomics with the viewpoints on the role of AI in terms of its promises for computational as well as oncological aspects and offers achievements and opportunities in the era of precision medicine. The review also presents various recommendations to diminish these obstacles.

11 January 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
SPSudip Paul
Sudip Paul
Mahesh A MaindarkarMahesh A Maindarkar
Mahesh A Maindarkar
Sanjay SaxenaSanjay Saxena
Sanjay Saxena
Luca SabaLuca Saba
Luca Saba
MTMonika Turk
Monika Turk
Jasjit SuriJasjit Suri
Jasjit Suri
Background and Motivation: Diagnosis of Parkinson’s disease (PD) is often based on medical attention and clinical signs. It is subjective and does not have a good prognosis. Artificial Intelligence (AI) has played a promising role in the diagnosis of PD. However, it introduces bias due to lack of sample size, poor validation, clinical evaluation, and lack of big data configuration. The purpose of this study is to compute the risk of bias (RoB) automatically. Method: The PRISMA search strategy was adopted to select the best 39 AI studies out of 85 PD studies closely associated with early diagnosis PD. The studies were used to compute 30 AI attributes (based on 6 AI clusters), using AP(ai)Bias 1.0 (AtheroPointTM, Roseville, CA, USA), and the mean aggregate score was computed. The studies were ranked and two cutoffs (Moderate-Low (ML) and High-Moderate (MH)) were determined to segregate the studies into three bins: low-, moderate-, and high-bias. Result: The ML and HM cutoffs were 3.50 and 2.33, respectively, which constituted 7, 13, and 6 for low-, moderate-, and high-bias studies. The best and worst architectures were “deep learning with sketches as outcomes” and “machine learning with Electroencephalography,” respectively. We recommend (i) the usage of power analysis in big data framework, (ii) that it must undergo scientific validation using unseen AI models, and (iii) that it should be taken towards clinical evaluation for reliability and stability tests. Conclusion: The AI is a vital component for the diagnosis of early PD and the recommendations must be followed to lower the RoB.


22 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BJBiswajit Jena
Biswajit Jena
Sanjay SaxenaSanjay Saxena
Sanjay Saxena
GNGopal Krishna Nayak
Gopal Krishna Nayak
ABAntonella Balestrieri
Antonella Balestrieri
NGNeha Gupta
Neha Gupta
Jasjit SuriJasjit Suri
Jasjit Suri
Brain tumor characterization (BTC) is the process of knowing the underlying cause of brain tumors and their characteristics through various approaches such as tumor segmentation, classification, detection, and risk analysis. The substantial brain tumor characterization includes the identification of the molecular signature of various useful genomes whose alteration causes the brain tumor. The radiomics approach uses the radiological image for disease characterization by extracting quantitative radiomics features in the artificial intelligence (AI) environment. However, when considering a higher level of disease characteristics such as genetic information and mutation status, the combined study of “radiomics and genomics” has been considered under the umbrella of “radiogenomics”. Furthermore, AI in a radiogenomics’ environment offers benefits/advantages such as the finalized outcome of personalized treatment and individualized medicine. The proposed study summarizes the brain tumor’s characterization in the prospect of an emerging field of research, i.e., radiomics and radiogenomics in an AI environment, with the help of statistical observation and risk-of-bias (RoB) analysis. The PRISMA search approach was used to find 121 relevant studies for the proposed review using IEEE, Google Scholar, PubMed, MDPI, and Scopus. Our findings indicate that both radiomics and radiogenomics have been successfully applied aggressively to several oncology applications with numerous advantages. Furthermore, under the AI paradigm, both the conventional and deep radiomics features have made an impact on the favorable outcomes of the radiogenomics approach of BTC. Furthermore, risk-of-bias (RoB) analysis offers a better understanding of the architectures with stronger benefits of AI by providing the bias involved in them.

13 December 2021 in Concurrency and Computation: Practice and Experience
Verified
Journal Article
Closed access
PDF file
BJBiswajit Jena
Biswajit Jena
GNGopal Krishna Nayak
Gopal Krishna Nayak
Sanjay SaxenaSanjay Saxena
Sanjay Saxena

31 March 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Jasjit SuriJasjit Suri
Jasjit Suri
SPSudip Paul
Sudip Paul
Mahesh A MaindarkarMahesh A Maindarkar
Mahesh A Maindarkar
APAnudeep Puvvula
Anudeep Puvvula
Sanjay SaxenaSanjay Saxena
Sanjay Saxena
KPKosmas I. Paraskevas
Kosmas I. Paraskevas
Parkinson’s disease (PD) is a severe, incurable, and costly condition leading to heart failure. The link between PD and cardiovascular disease (CVD) is not available, leading to controversies and poor prognosis. Artificial Intelligence (AI) has already shown promise for CVD/stroke risk stratification. However, due to a lack of sample size, comorbidity, insufficient validation, clinical examination, and a lack of big data configuration, there have been no well-explained bias-free AI investigations to establish the CVD/Stroke risk stratification in the PD framework. The study has two objectives: (i) to establish a solid link between PD and CVD/stroke; and (ii) to use the AI paradigm to examine a well-defined CVD/stroke risk stratification in the PD framework. The PRISMA search strategy selected 223 studies for CVD/stroke risk, of which 54 and 44 studies were related to the link between PD-CVD, and PD-stroke, respectively, 59 studies for joint PD-CVD-Stroke framework, and 66 studies were only for the early PD diagnosis without CVD/stroke link. Sequential biological links were used for establishing the hypothesis. For AI design, PD risk factors as covariates along with CVD/stroke as the gold standard were used for predicting the CVD/stroke risk. The most fundamental cause of CVD/stroke damage due to PD is cardiac autonomic dysfunction due to neurodegeneration that leads to heart failure and its edema, and this validated our hypothesis. Finally, we present the novel AI solutions for CVD/stroke risk prediction in the PD framework. The study also recommends strategies for removing the bias in AI for CVD/stroke risk prediction using the PD framework.